Navigation Links
HemCon Medical Technologies, Inc. signs exclusive global agreement with Zimmer Dental Inc. to distribute oral surgery dressings
Date:9/15/2009

HemCon® Dental Dressings are now available in many global oral surgery markets.

Portland, Ore. (Vocus) September 15, 2009 -- HemCon Medical Technologies, Inc. ("HemCon"), a leading developer of advanced medical products, is proud to announce the signing of an exclusive global distribution agreement with Zimmer Dental Inc., a leading provider of dental oral rehabilitation products and a subsidiary of Zimmer Holdings, Inc. Through this agreement, Zimmer Dental will supply HemCon's line of revolutionary oral wound care dressings for all dental applications throughout the globe.

HemCon Dental Dressings are based on HemCon's unique chitosan platform technology which is most notably being used as the basis for their proprietary hemorrhage control bandages on the battlefield and in acute care settings. HemCon Dental Dressings effectively seal any oral wound and minimize pain in various dental, periodontal, and oral surgery procedures, culminating in a more positive experience for both clinicians and patients.

"HemCon is excited to aggressively pursue these markets with a strong partner like Zimmer Dental whose hundreds of global sales representatives will assist in penetrating key markets around the world," said HemCon CEO John W. Morgan. "Along with our hemostatic HemCon® dressings, our HemCon Dental Dressings will broaden the positive impact our technological innovations offer to improve care for patients on a global scale."

For decades, Zimmer Dental has gained the trust of thousands of clinicians worldwide who count on its comprehensive line of scientifically-proven products to deliver successful patient outcomes and the best value in the industry. "We have been looking for a new innovative product to broaden the scope of our industry-leading family of regenerative products," said Harold C. Flynn, Jr., Zimmer Dental's President. "We feel that the HemCon Dental Dressing reinforces Zimmer Dental's ongoing goal of empowering clinicians and shaping the future of implant dentistry."

About HemCon Medical Technologies Inc.
HemCon Medical Technologies Inc. is a leading global developer of advanced medical products designed to improve the standard of patient care. The company is responsible for developing the chitosan-based HemCon dressing used by thousands of military and civilian first responders and is changing wound care best practices in hospital, dental and clinical settings. In addition, HemCon is leading the charge to develop and license unique, life-saving medical advances including lyophilized human plasma and nanofiber technologies for wound care. HemCon is headquartered in Portland, Ore., with additional commercial operations in Ireland, England, Germany and the Czech Republic. For more information, please visit www.hemcon.com.

Public Relations Contact:
Simona Buergi   
HemCon Medical Technologies Inc.
503-245-0459      

# # #

Read the full story at http://www.prweb.com/releases/HemCon/Zimmer_Dental/prweb2882044.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Hemostatic HemCon Dressings Selected by the Premier Healthcare Alliance for Hemostasis Products Contract
2. New HemCon/Seal-On Nasal Plugs Control Nosebleeds Quickly, Effectively and Comfortably
3. ConvaTec and HemCon Announce Co-Promotion Agreement
4. Texas Cardiac Arrhythmia Institute at St. Davids Medical Center Orders 4 Odyssey Systems
5. Medical Imaging Equipment Finds Significant Uptake in Ghana, Finds Frost & Sullivan
6. AirMed Asia has Entered into a Joint Venture Agreement with Asia Air Medical to Expand Air Medical Transport in China
7. Veterinarian Group Launches New Website to Help Pet Owners With Medical Advice and the Best Vet-Approved Products
8. MedEncentive and Medical Justice Announce Partnership
9. PolyOne Presented with Frost & Sullivan Medical Product Award
10. Center for AIDS Intervention Research Medical receives $11.16 million NIH grant
11. Ronald O. Perelman Heart Institute of NewYork-Presbyterian Hospital/Weill Cornell Medical Center Opens as a Center for Innovative, World-Class Cardiac Care and Patient Education
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
HemCon Medical Technologies, Inc. signs exclusive global agreement with Zimmer Dental Inc. to distribute oral surgery dressings 
(Date:2/23/2017)... FL (PRWEB) , ... February 23, 2017 , ... ... non-profit organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma ... – will return to the La Gorce Country Club in Miami Beach to ...
(Date:2/23/2017)... ... February 23, 2017 , ... Los Angeles-based weight loss ... WE TV’s “Mama June: From Not to Hot,” which will begin airing on February ... Shannon, known to millions from the 2012 reality television series, “Here Comes Honey Boo ...
(Date:2/23/2017)... ... February 23, 2017 , ... EBSCO ... the National Institute for Health and Care Excellence (NICE) framework. The ... National Health Service (NHS) to search, order and purchase medical and healthcare-related content ...
(Date:2/23/2017)... ... 2017 , ... Pink Pig Publishing LLC announces the launch ... the world from different perspectives. By providing a place for people of all ... empathy, and find greater happiness. , "Our approach to structuring content is ...
(Date:2/23/2017)... NJ (PRWEB) , ... February 23, 2017 , ... ... the pre-eminent publication and community for those in the fight against cancer, has ... important in their success. HRA will release top-line findings in a webinar, ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... , Feb. 23, 2017 Non-alcoholic ... on the various drugs being developed for ... all the drugs that are in various ... The pipeline focuses on novel pharmacologic drugs ... stem cell therapies, recombinant proteins and RNA-based ...
(Date:2/24/2017)... , Feb. 24, 2017  Xynomic Pharmaceuticals, Inc., ... announced that it has acquired exclusive worldwide rights ... best-in-class innovative HDAC inhibitor targeting hematological and solid ... 14 Phase 1 and 2 clinical trials of ... have already been completed, demonstrating that ...
(Date:2/23/2017)... DUBLIN , Feb 23, 2017 Research ... Disorder Drugs Price Analysis and Strategies - 2016" report to ... ... - 2016, provides drug pricing data and benchmarks in the global ... What are the key drugs marketed ...
Breaking Medicine Technology: